Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Regenerx Biopharmaceuticals has completed enrollment and dosing of 40 healthy subjects for its Phase Ia clinical trial testing RGN-352, an injectable formulation of Tâ4 for potential use in treating acute myocardial infarction patients.
Subscribe to our email newsletter
The trial includes four groups of 10 subjects each to assess the safety of escalating doses of RGN-352 injected into the blood stream. A final analysis and report will be completed after 28 days of follow-up of the last subject.
RegeneRx expects to initiate the second part of Phase I with a Phase Ib trial in the third quarter 2008 after submitting a Ia report to the FDA. The Ib trial design is similar to Ia; however, the 40 subjects will be dosed once daily for 14 days, rather than given only a single dose, and will undergo a 28-day and a six-month follow-up.
Finkelstein, president and CEO of Regenerx, said: “This trial is intended to provide the safety data for Phase II clinical trials that are being planned to evaluate RGN-352 for the treatment of patients immediately after an acute myocardial infarction and also to support other potential uses of RGN-352 in medical indications where short-term systemic administration of the drug candidate may be warranted.”